SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$364M
Q2 2021
Positions
57
Filings on Record
24
2019–present window
Filed
Aug 27, 2021
amendment (RESTATEMENT)

Summary

Endurant Capital Management LP reported $364M in U.S.-listed holdings across 57 positions for Q2 2021.

Its largest position, Invacare, represents 10.1% of the portfolio.

Compared with Q1 2021, the fund opened 22 new positions and exited 26.

Portfolio Metrics

Turnover
+49.8%
vs prior filed quarter
Top-10 Concentration
+44.4%
share of reported value
Largest Position
+10.1%
Invacare
New / Exited
22 / 26
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.3%Other: 15.6%US DOMESTIC: 11.6%ADR: 2.5%
  • Common Stock · 70.3% · $256M
  • Other · 15.6% · $57M
  • US DOMESTIC · 11.6% · $42M
  • ADR · 2.5% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CICIGNA CORP NEWNEW+71.9K71.9K+$17M$17M
ICON PLCNEW+79.4K79.4K+$16M$16M
TMOTHERMO FISHER SCIENTIFIC INCNEW+29.7K29.7K+$15M$15M
THCTENET HEALTHCARE CORPNEW+217.9K217.9K+$15M$15M
EARGO INCNEW+193.5K193.5K+$8M$8M
HO1HOLOGIC INCNEW+110.8K110.8K+$7M$7M
HUMHUMANA INCNEW+15.8K15.8K+$7M$7M
XRAYDENTSPLY SIRONA INCNEW+103.9K103.9K+$7M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IVCUSDINVACARE CORPNOTE 5.000%11/1 · COM13.12%$48M38.94M
2LABORATORY CORP AMER HLDGSCOM NEW4.77%$17M62.9K
3CICIGNA CORP NEWhistory →COM4.68%$17M71.9K
4ICON PLCSHS4.51%$16M79.4K
5TMOTHERMO FISHER SCIENTIFIC INChistory →COM4.11%$15M29.7K
6THCTENET HEALTHCARE CORPhistory →COM NEW4.01%$15M217.9K
7IM8NINSMED INCCOM PAR $.01 · NOTE 0.750% 6/03.56%$13M5.26M
8RCMEURR1 RCM INChistory →COM3.36%$12M548.9K
98INSYNEOS HEALTH INChistory →CL A3.20%$12M130.2K
10ABBVABBVIE INChistory →COM2.65%$10M85.5K
11ELUTAZIYO BIOLOGICS INChistory →COM CL A2.31%$8M873.2K
12OCULOCULAR THERAPEUTIX INChistory →COM2.23%$8M571.0K
13PHASEURPHASEBIO PHARMACEUTICALS INChistory →COM2.18%$8M2.13M
14HAEHAEMONETICS CORP MASShistory →COM2.16%$8M117.9K
15EARGO INCCOM2.12%$8M193.5K
16BUWABIO RAD LABS INChistory →CL A2.09%$8M11.8K
17HO1HOLOGIC INChistory →COM2.03%$7M110.8K
18HUMHUMANA INChistory →COM1.92%$7M15.8K
19BMYBRISTOL-MYERS SQUIBB COhistory →COM1.86%$7M101.1K
20XRAYDENTSPLY SIRONA INChistory →COM1.81%$7M103.9K
21ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR1.80%$7M1.54M
22MOLECULAR TEMPLATES INCCOM1.61%$6M748.0K
23TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.60%$6M600.8K
24VCYTVERACYTE INChistory →COM1.54%$6M140.2K
25DRIOEURDARIOHEALTH CORPhistory →COM NEW1.52%$6M258.8K
26JNJJOHNSON & JOHNSONhistory →COM1.49%$5M33.0K
27AVTRAVANTOR INChistory →COM1.49%$5M152.4K
28ABGAMERISOURCEBERGEN CORPhistory →COM1.31%$5M41.7K
29ELVANTHEM INChistory →COM1.25%$5M11.9K
30FATEFATE THERAPEUTICS INChistory →COM1.22%$4M51.0K
31SPRYSILVERBACK THERAPEUTICS INChistory →COM1.18%$4M139.1K
32CALLIDITAS THERAPEUTICS ABSPONSERED ADS1.17%$4M144.4K
33IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.15%$4M160.4K
34SELECTA BIOSCIENCES INCCOM1.07%$4M926.9K
35PRAXIS PRECISION MEDICINES ICOM1.00%$4M199.6K
36BDQMALBIREO PHARMA INChistory →COM1.00%$4M103.5K
37MEDAVAIL HOLDINGS INCCOM0.98%$4M292.2K
38REGNREGENERON PHARMACEUTICALSCOM0.85%$3M5.6K
39TFXTELEFLEX INCORPORATEDCOM0.83%$3M7.5K
40ACHOWENS & MINOR INC NEWCOM0.78%$3M67.0K
41MREOMEREO BIOPHARMA GROUP PLCADS0.66%$2M756.9K
42SRPTSAREPTA THERAPEUTICS INCCOM0.61%$2M28.6K
43VTLUSDIMMUNIC INCCOM0.60%$2M177.1K
44RGLSUSDREGULUS THERAPEUTICS INCCOM NEW0.58%$2M2.61M
45ACRSACLARIS THERAPEUTICS INCCOM0.58%$2M119.4K
46BAXBAXTER INTL INCCOM0.55%$2M25.1K
47PNTGPENNANT GROUP INCCOM0.53%$2M47.5K
48TOCAEURFORTE BIOSCIENCES INCCOM0.49%$2M53.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.